NASDAQ:TARS - Tarsus Pharmaceuticals Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $54.00
  • Forecasted Upside: 285.99 %
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 3 Buy Ratings
  • 1 Strong Buy Ratings
$13.99
▲ +0.29 (2.12%)

This chart shows the closing price for TARS by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Tarsus Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for TARS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for TARS

Analyst Price Target is $54.00
▲ +285.99% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Tarsus Pharmaceuticals in the last 3 months. The average price target is $54.00, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a 285.99% upside from the last price of $13.99.

This chart shows the closing price for TARS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 4 contributing investment analysts is to buy stock in Tarsus Pharmaceuticals.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 1 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/30/2020
  • 1 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/28/2021
  • 1 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/29/2021
  • 1 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/27/2021
  • 1 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/25/2021
  • 1 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/23/2022
  • 1 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/24/2022
  • 1 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/24/2022

Latest Recommendations

  • 1 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/3/2022HC WainwrightReiterated RatingBuy$40.00High
5/2/2022OppenheimerBoost Price Target$55.00 ➝ $66.00High
3/17/2022HC WainwrightReiterated RatingBuy$40.00High
12/21/2021HC WainwrightInitiated CoverageBuy$40.00High
11/22/2021OppenheimerInitiated CoverageOutperform$55.00High
10/7/2021Raymond JamesBoost Price TargetStrong-Buy$50.00 ➝ $65.00High
6/29/2021Raymond JamesBoost Price TargetStrong-Buy$39.00 ➝ $50.00High
6/22/2021Jefferies Financial GroupBoost Price TargetBuy$35.00 ➝ $45.00High
6/17/2021Raymond JamesReiterated RatingBuyMedium
11/10/2020Lifesci CapitalReiterated RatingOutperformMedium
11/10/2020Raymond JamesInitiated CoverageStrong-Buy$39.00High
11/10/2020Jefferies Financial GroupInitiated CoverageBuy$35.00High
11/10/2020LADENBURG THALM/SH SHInitiated CoverageBuy$42.00High
11/10/2020Bank of AmericaInitiated CoverageBuy$33.00High
(Data available from 5/24/2017 forward)

News Sentiment Rating

0.41 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/26/2021
  • 5 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/25/2021
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/25/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/24/2022
  • 5 very positive mentions
  • 0 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
2/23/2022
  • 0 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
3/25/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/24/2022
  • 9 very positive mentions
  • 15 positive mentions
  • 4 negative mentions
  • 2 very negative mentions
5/24/2022

Current Sentiment

  • 9 very positive mentions
  • 15 positive mentions
  • 4 negative mentions
  • 2 very negative mentions

Recent Stories by Sentiment

Tarsus Pharmaceuticals logo
Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. The company is also developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other diseases. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.
Read More

Today's Range

Now: $13.99
Low: $13.56
High: $14.12

50 Day Range

MA: $16.27
Low: $11.08
High: $19.08

52 Week Range

Now: $13.99
Low: $10.80
High: $39.08

Volume

212,473 shs

Average Volume

109,027 shs

Market Capitalization

$289.97 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.45

Frequently Asked Questions

What sell-side analysts currently cover shares of Tarsus Pharmaceuticals?

The following Wall Street research analysts have issued stock ratings on Tarsus Pharmaceuticals in the last twelve months: HC Wainwright, Jefferies Financial Group Inc., Oppenheimer Holdings Inc., Raymond James, and Zacks Investment Research.
View the latest analyst ratings for TARS.

What is the current price target for Tarsus Pharmaceuticals?

0 Wall Street analysts have set twelve-month price targets for Tarsus Pharmaceuticals in the last year. Their average twelve-month price target is $54.00, suggesting a possible upside of 286.0%.
View the latest price targets for TARS.

What is the current consensus analyst rating for Tarsus Pharmaceuticals?

Tarsus Pharmaceuticals currently has 3 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe TARS will outperform the market and that investors should add to their positions of Tarsus Pharmaceuticals.
View the latest ratings for TARS.

How do I contact Tarsus Pharmaceuticals' investor relations team?

The company's listed phone number is 949-409-9820 and its investor relations email address is [email protected] The official website for Tarsus Pharmaceuticals is www.tarsusrx.com. Learn More about contacing Tarsus Pharmaceuticals investor relations.